TapImmune Inc (NASDAQ:TPIV) shares rose 2.77% on Tuesday to $2.97 and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $2.81 to $11.64. The company has a market cap of $30.17 million at 10.16 million shares outstanding.
In a press release, TapImmune Inc announced that, in coordination with the U.S. Food and Drug Administration, it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy.
The company has enrolled the first women under this amended study protocol, which expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.
“Our investigators, as well as their ovarian cancer patients, are enthusiastic about this trial, which is intended to demonstrate enhanced progression-free survival for women prior to their first recurrence,” said Dr. Richard Kenney, Head of Clinical Development at TapImmune Inc.
“Shifting our focus to earlier in the treatment cycle enables TapImmune to showcase the potential of our novel T cell vaccine in a much larger patient population. Furthermore, should TPIV 200 demonstrate a significant benefit for these women in prolonging the time to disease recurrence, the Company will be well positioned within the current treatment paradigm for ovarian cancer, which now includes the PARP inhibitor niraparib for treating patients with recurrent disease,” he continued.
TapImmune Inc is an immuno-oncology company that specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The company is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers.
As such, it combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA) expression technologies that improve the ability of the cellular immune system to recognize and destroy diseased cells.
The company’s core technology platforms include TPIV 100/110, a vaccine for the treatment of Human Epidermal Growth Factor receptor 2 (HER2)/neu+ breast cancer that over-expresses HER2/neu; TPIV 200, a vaccine for treating breast and ovarian cancers that over-express Folate Receptor Alpha, and DNA expression vaccine technology (Polystart) for further treating various cancers or infectious disease.